Rituximab Maintenance Delays Need for More Aggressive Treatment in Follicular Lymphoma

Researchers sponsored in part by Cancer Research UK explored whether patients with advanced-stage, low tumor burden follicular lymphoma could benefit from rituximab.

Rituximab has the potential to delay the need for chemotherapy or radiotherapy in a more proactive manner as compared to the current protocol of watchful waiting. They also explored whether this strategy had an effect on quality of life.

The study recruited 379 patients from 118 centers in the U.K., Australia, New Zealand, Turkey, and Poland. They were randomly assigned either to watchful waiting or maintenance rituximab.

Initially, 84 patients were recruited to rituximab induction, in which they received rituximsb once a week for four weeks but the arm was closed early.

Investigators found a significant difference in the time to start of new treatment at three years:

  • 46 percent of patients in the watchful waiting group did not need treatment at three years
  • 88 percent in the maintenance rituximab group did not need treatment at three years
  • 78 percent in the rituximab induction group did not need treatment at three years

Rituximab should be considered as a treatment option

Compared with the watchful waiting group, patients in the maintenance rituximab group had significant improvements in the Mental Adjustment to Cancer scale score, and Illness Coping Style score between baseline and month 7. Patients in the rituximab induction group did not show improvements in their quality of life compared with the watchful waiting group.

There were 18 serious adverse events reported in the rituximab groups (four in the rituximab induction group and 14 in the maintenance rituximab group), 12 of which were grade 3 or 4 (five infections, three allergic reactions, and four cases of neutropenia), all of which fully resolved.

Researchers concluded that rituximab monotherapy should be considered as a treatment option for patients with asymptomatic, advanced-stage, low tumor burden follicular lymphoma.

Source: The Lancet

More Articles

More Articles

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Cancer bracelets are undeniably popular, and if purchased through reliable sources such as major charities, they help contribute to the fight...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer of the b- and t-cell lymphocytes, part of the immune system. They account for the most frequent head and neck malignancies....

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

As a kind of cancer, lymphoma attacks the lymphocytes and lymph nodes that are part of the immune system. Head and neck lymphoma results when...

Some cancers have clear environmental causes. Oral cancer is strongly tied to the use of chewing tobacco, and lung cancer is well-known to be much...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...